Dong WeiPh.D., MBA
Acting Head of Clinical Development (China)
Dr. Dong Wei joined EdiGene as CEO in 2018, a biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer.
Prior to EdiGene, Dr. Wei had over 20 years of experience in innovative drug development and management, including leading over 10 global clinical-stage programs in multiple therapeutic areas at BioMarin, Elan, Johnson & Johnson and Shire, advising healthcare and life science clients on strategic and operational issues at Deloitte Consulting, as well as conducting drug discovery and technology development at Chiron and Applied Biosystems.
He holds BS in Genetics from Peking University, Ph.D. in Microbiology from Michigan State University and MBA from the Wharton School of University of Pennsylvania.